文献速递泌尿男性生殖肿瘤

嫌色细胞肾细胞癌抗肿瘤免疫受损的肿瘤内在与微环境决定因素

Tumor-Intrinsic and Microenvironmental Determinants of Impaired Antitumor Immunity in Chromophobe Renal Cell Carcinoma.
PubMed 文献 · J Clin Oncol · 2025-07-02

本研究通过单细胞转录组和T细胞受体分析,结合机器学习与免疫组化,发现嫌色细胞肾细胞癌(ChRCC)中HLA I类分子下调、免疫浸润显著减少、CD8+ T细胞克隆扩增和肿瘤特异性降低,且转移性ChRCC患者接受免疫治疗生存结局较差,提示ChRCC为免疫冷肿瘤,需定制治疗策略。

要点

  • ChRCC肿瘤微环境免疫浸润显著减少,CD8+ T细胞明显耗竭。
  • ChRCC浸润CD8+ T细胞免疫检查点表达、克隆扩增和肿瘤特异性均降低。
  • 转移性ChRCC患者接受免疫为基础治疗生存结局较差。

核心结论

  • ChRCC免疫基因组分析显示T细胞严重耗竭,免疫表型以免疫检查点表达缺失和肿瘤特异性差为特征,提示这些肿瘤中少量T细胞可能为非特异性旁观者。
  • 这种免疫冷环境阻碍对免疫治疗的有效反应,强调需要为ChRCC定制旨在改善肿瘤特异性T细胞浸润微环境的治疗。

研究设计与样本

  • 对ChRCC和肾嗜酸细胞肿瘤患者的肿瘤及癌旁正常组织进行单细胞转录组和T细胞受体分析。
  • 使用机器学习评估肾嗜酸细胞肿瘤的细胞起源并分析相关致癌通路。
  • 使用免疫组化分析肾嗜酸细胞肿瘤免疫浸润并与透明细胞肾细胞癌(ccRCC)比较。
  • 比较ChRCC与ccRCC的免疫检查点表达、克隆扩增和肿瘤特异性。
  • 使用国际转移性RCC数据库联盟数据集比较转移性ChRCC(mChRCC)患者一线系统治疗与ccRCC患者的临床结局。

主要发现

  • 验证α-闰细胞为肾嗜酸细胞肿瘤的细胞起源。
  • ChRCC中HLA I类分子下调,富集包括哺乳动物雷帕霉素靶蛋白和铁死亡在内的潜在可靶向通路。
  • ChRCC肿瘤微环境免疫浸润显著减少,肿瘤浸润CD8+ T细胞明显耗竭。
  • ChRCC浸润CD8+ T细胞免疫检查点表达更低、克隆扩增减弱、肿瘤特异性降低。
  • 临床分析发现仅在接受免疫为基础治疗的mChRCC患者中生存结局较差。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: While immune checkpoint inhibition (ICI) has transformed the management of many advanced renal cell carcinomas (RCCs), the determinants of effective antitumor immunity for chromophobe RCC (ChRCC) and renal oncocytic tumors remain an unmet clinical and scientific need. METHODS: Single-cell transcriptomic and T-cell receptor profiling was performed on tumor and adjacent normal tissue of patients with ChRCC and renal oncocytic neoplasms. Using machine learning, the cellular origin of renal oncocytic neoplasms was evaluated, with analysis of associated oncogenic pathways. Using immunohistochemistry, immune infiltration was analyzed in renal oncocytic neoplasms in comparison with clear cell RCC (ccRCC). Immune checkpoint expression, clonal expansion, and tumor specificity were compared between ChRCC and ccRCC. Using the International Metastatic RCC Database Consortium data set, clinical outcomes of patients with metastatic ChRCC (mChRCC) treated with first-line systemic regimens were compared with those of patients with ccRCC. RESULTS: We validated α-intercalated cells as the cellular origin of renal oncocytic neoplasms. We identified a downregulation of HLA class I molecules with enrichment of potentially targetable pathways including mammalian target of rapamycin and ferroptosis in ChRCC. The tumor microenvironment of ChRCC showed markedly decreased immune infiltration, with a pronounced depletion in tumor-infiltrating CD8+ T cells. ChRCC-infiltrating CD8+ T cells demonstrated lower immune checkpoint expression, diminished clonal expansion, and decreased tumor specificity. Clinical analysis identified poor survival outcomes selectively among patients with mChRCC treated with immune-based therapies. CONCLUSION: Immunogenomic analysis of ChRCC revealed profound depletion of T cells, with an immune phenotype marked by a lack of expression of immune checkpoints and poor tumor specificity, suggesting that the few T cells in these tumor types are likely nonspecific bystanders. This immune-cold environment hinders an effective response to immunotherapy and underscores the need for ChRCC-tailored treatments designed to improve tumor-specific T-cell infiltration into the microenvironment.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Labaki C, Saad E, Madsen KN, et al. Tumor-Intrinsic and Microenvironmental Determinants of Impaired Antitumor Immunity in Chromophobe Renal Cell Carcinoma. J Clin Oncol. 2025. PMID: 40601888. doi:10.1200/JCO-25-00234

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。